secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038592
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients
--------------------------------------------------------------------------------

- Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).
- Phase 1 ELIMINATE-B trial: PBGENE-HBV showed 47-69% HBsAg reduction in all 3 Cohort 1 patients; one patient had durable ~50% reduction at 7 months.
- Cohort 2 safety data showed no Grade>2 AEs; DMC recommended enrolling Cohort 3. Cash runway extended to H2 2027 via operating cost cuts of ~$25M/year.
- PBGENE-DMD: FDA granted Rare Pediatric Disease and Orphan Drug designations; IND/CTA filing targeted by end of 2025 with clinical data in 2026.
- Total operating expenses fell $3.9M YoY to $21.9M; cash and equivalents $84.8M as of June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828025038592/0001628280-25-038592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828025038592/dtil-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer